May 16, 2022
Article
There is a role for these overlapping entities—guidelines and pathways—and each permits flexibility for the oncologist for available treatment options in the level and quality of data.
April 07, 2022
Article
Using combination treatments in the concurrent setting with chemotherapy, radiation therapy, or small molecule oncogene and pathway inhibitors may yield positive data in one setting but not another.
February 13, 2022
Article
According to Robert L. Ferris, MD, PhD, there is a steady pace of drug development for head and neck cancers despite modest findings with durvalumab triplet.
January 31, 2022
Article
In-person interactions enrich and eventually improve the outcomes that we are able to provide to our trainees, and thus to patients and the field of oncology.
September 16, 2021
Article
The field is ripe for preventing the undesirable long-term effects of cancer treatment or reducing them altogether through de-intensification, according to Robert L. Ferris, MD, PhD.
July 03, 2021
Article
It has taken some decades, but the identification of targets such as HER2 has enabled us to segregate cancers into different subtypes, develop novel therapeutic strategies, and eventually understand the biology distinguishing one group of patients from another, says Robert L. Ferris, MD, PhD.